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■ Abstract
Background: Hazelnut (Corylus avellana) allergy exhibits age and geographically distinct sensitization patterns that have not yet been fully resolved. 
Objective: To study sensitization to Cor a 11 in different age groups of hazelnut-allergic patients and infants with atopic dermatitis (AD) 
sensitized to hazelnut in a birch-endemic region.
Methods: Sera from 80 hazelnut-allergic patients, 33 infants under 1 year of age with AD (24 sensitized and 9 not sensitized to hazelnut), 
32 healthy control individuals, and 29 birch pollen–allergic but hazelnut-tolerant individuals were tested for immunoglobulin (Ig) E reactivity 
to Cor a 11 by ImmunoCAP. IgE reactivity to Cor a 1.01, Cor a 1.04, Cor a 8, and Cor a 9 was studied by ISAC microarray. 
Results: Forty patients (22 preschool children, 10 schoolchildren, and 8 adults) with systemic reactions on consumption of hazelnut were 
sensitized to Cor a 11 (respective rates of 36%, 40%, and 12.5%). Forty patients (6 preschool children, 10 schoolchildren, and 24 adults) 
reported oral allergy syndrome but only 2 of them (of preschool age) were sensitized to Cor a 11. 
Two (8%) of the AD infants sensitized to hazelnut showed IgE reactivity to Cor a 11. This reactivity was not observed in any of the AD infants 
without sensitization to hazelnut, in any of the birch-pollen allergic patients without hazelnut allergy, or in any of the healthy control individuals. 
Conclusion: Sensitization to Cor a 11 in a birch-endemic region is predominantly found in children with severe hazelnut allergy, a fi nding 
that is consistent with observations concerning sensitization to Cor a 9. 
Key words: Basophil activation. Birch. Cor a 11. Component-resolved diagnosis. Hazelnut. IgE.
■ Resumen
Introducción: La alergia a avellana (Corylus avellana) exhibe unos patrones de sensibilización diferentes según la edad y área geográfi ca 
que no han sido totalmente elucidados. 
Objetivos: El objetivo de este estudio fue analizar la sensibilización frente a Cor a 11 en diferentes grupos de edad en pacientes adultos y 
en niños con dermatitis atópica (DA) sensibilizados a avellana procedentes de un área geográfi ca endémica
Métodos: Se cuantifi có la IgE específi ca frente a Cor a 11 mediante ImmunoCAP en sueros procedentes de 80 pacientes alérgicos a 
avellana, 33 niños menores de 1 año con DA, (24 sensibilizados y 9 no sensibilizados a avellana), 32 controles sanos y 29 alérgicos a polen 
y tolerantes a avellana. Además se evaluó la IgE específi ca frente a Cor a 1.01, Cor a 1.04, Cor a 8, y Cor a 9 mediante microarray ISAC. 
Resultados: Cuarenta pacientes (22 niños preescolares, 10 escolares y 8 adultos) con reacciones sistémicas tras la ingesta de avellana, 
estaban sensibilizados a Cor a 11 (36%,40%,12.5% respectivamente). Cuarenta pacientes (6 preescolares, 10 escolares y 24 adultos) 
tenían síndrome de alergia oral, pero únicamente dos de ellos (preescolares) estaban sensibilizados a Cor a 11. Dos (8%) de los niños con 
DA sensibilizados a avellana mostraban reactividad a Cor a 11. Esta reactividad no se observó en ningún niño con DA sin sensibilización 
a avellana, o en los pacientes alérgicos a polen de abedul sin alergia a avellana o en los controles sanos.
Conclusiones: En conclusión la sensibilización a Cor a 11 se encuentra de forma predominante en niños con alergia grave a avellana, en 
una población endémica de abedul y es consistente con las observaciones concernientes a la sensibilización a Cor a 9.
Palabras clave: Activación de basófi los. Abedul. Cor a 11. Diagnóstico por componentes. Avellana. IgE.
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Introduction
Hazelnut constitutes an important food allergy in children 
and adults [1-3] with geographic and age-related variations in 
clinical severity according to the sensitization profi le of the 
patient [4-6]. In birch-endemic regions, hazelnut allergy is 
predominantly observed in adults with oral allergy syndrome 
(OAS) due to cross-reactivity between Cor a 1.04 and Bet v 1, 
the major allergen from birch (Betula verrucosa) pollen [4-8]. 
The more severe, systemic reactions seen in adults from 
Mediterranean regions and children from birch-endemic 
regions are generally not associated with pollen allergy and are 
frequently related to sensitization to the hazelnut lipid transfer 
protein (LTP) Cor a 8 [6,8-10] or the 11S legumin-like seed-
storage protein Cor a 9 [4,6,11]. Sensitization to Cor a 8 and 
Cor a 9 can also occur in young children [10,12].
However, 2 studies have shown that sensitization patterns 
remain to be elucidated in 40% of children with severe pollen-
unrelated hazelnut allergy [4] and infants with atopic dermatitis 
(AD) sensitized to hazelnut [12]. Recently, the hazelnut 2S albumin 
Cor a 14 [8,13], the 7S vicilin-like protein Cor a 11 [6,14], and 
oleosin [15] were also identifi ed as allergenic components. 
Data on the prevalence and clinical relevance of sensitization to 
Cor a 11 are divergent and restricted to adults with OAS [6,14]. 
The aim of this study was to establish sensitization rates 
to Cor a 11 in children and adults with hazelnut allergy and 
in infants with AD sensitized to hazelnut in birch-endemic 
regions.
 
Materials and Methods
Study Participants
A total of 174 individuals were studied. Eighty consecutive 
patients with a compelling history of immediate allergic 
symptoms upon consumption of raw or processed hazelnut 
were enrolled and stratifi ed into 6 groups according to both 
age (0-6 years, 7-18 years, and >18 years) and clinical severity 
(OAS or systemic reactions) [4]. 
To assess possible differences in sensitization patterns 
between patients with genuine hazelnut allergy and those with 
mere sensitization to hazelnut, 29 patients with documented 
birch pollen allergy who did not develop symptoms on eating 
hazelnut were also studied, as was a control group of 27 
nonallergic, nonsensitized age-matched individuals. 
Sera from 33 infants under the age of 1 year with AD and 
sensitization to cow’s milk, hen’s egg, wheat, soy, potato, or 
peanut were selected as described elsewhere [12]. Twenty-four 
of the infants (17 males; median age, 9 months [range, 4-11 
months]) showed specifi c immunoglobulin (sIg) E reactivity to 
hazelnut by Cor a 1.04-spiked ImmunoCAP. The remaining 9 
infants (all male; median age 6.5 months [range, 5-11 months]) 
had negative IgE to hazelnut. Additionally, sera of 5 healthy 
control infants (4 males; median age, 8 months [range, 5-11 
months]) without AD or sensitization to any of the above-
mentioned food allergens were studied. 
All the patients and controls, or their legal guardians, 
completed a standardized questionnaire about symptoms 
following the consumption of hazelnut or hazelnut-containing 
foods. Challenges were not conducted in patients with systemic 
reactions due to the severity of the reported symptoms and 
the consequential potential risk of eliciting serious reactions 
[6,11,16]. In OAS, challenges were deemed unnecessary 
as the clinical history in such cases is highly reliable and 
symptoms are easily recognized and described by the 
patient [17].
The local ethics committee approved the study and all the 
participants (or their legal representatives) gave their informed 
consent in accordance with the Declaration of Helsinki.
Purifi cation of Cor a 11
Nine different brands of hazelnut were purchased in local 
supermarkets; eight brands were raw, non-roasted hazelnuts 
and one was roasted. A hazelnut mixture was made by taking 
equal amounts from each brand. The hazelnuts were frozen 
with liquid nitrogen and ground fi rst with a blender (Moulinex) 
and then with an Ultra Turrax t25 (IKA). The hazelnut vicilin 
Cor a 11 was isolated using a modifi cation [18] of the original 
protocol described by Rigby et al [19]. The purity of Cor a 11 
was assessed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and gel fi ltration chromatography. 
Total and Specifi c IgE
Singleplexed Assay
Total IgE and sIgE to the Cor a 1.04-supplemented hazelnut 
extract and bromelain were quantified according to the 
manufacturer’s instructions (FEIA ImmunoCAP, Phadia). The 
ImmunoCAP bromelain was used as a marker for sensitization 
to MUXF cross-reactive carbohydrate determinants (CCDs). 
Purified nCor a 11 was coupled to ImmunoCAPs by 
ThermoFisher Phadia. Allergen-specifi c IgE levels of 0.10 
kUA/L or higher were regarded as positive (Table 1).
Multiplexed Assay (CRD Microarray)
An allergen microarray immunoassay containing 103 
components (ImmunoCAP ISAC, Phadia) to determine 
sensitization profi les was employed as described previously [4]. 
Results were expressed as ISAC Standardized Units (ISU/L) 
and values of greater than 0 were regarded as positive. 
Recombinant components are denoted by ‘r’ and natural 
purifi ed proteins by ‘n’. 
Basophil Activation Test
The basophil activation test (BAT) is described 
elsewhere [4]. Briefl y, blood samples were stimulated with 
4 concentrations of purifi ed Cor a 11 (0.001, 0.01, 0.1, and 
1 μg/mL) and a positive control (anti-human IgE, 10 μg/mL, 
BD Biosciences) or buffer (Gibco, Invitrogen) to measure 
spontaneous CD63 expression. Analysis of basophil activation 
was performed using side scatter, CD123+ and HLA-DR- to 
gate out the basophils. Within this gate, the percentage of 
activated basophils, ie, those expressing CD63, was measured. 
Results were expressed as percentages of CD63+ basophils 
after subtraction of the negative control value.
Hazelnut Allergy: Sensitization to Cor a 11
 J Investig Allergol Clin Immunol 2012; Vol. 22(4): 245-251© 2012 Esmon Publicidad
247
Ta
bl
e 
1.
 C
ha
ra
ct
er
ist
ics
 o
f C
hi
ld
re
n 
an
d 
Ad
ul
ts
 S
tra
tifi
 e
d 
by
 C
lin
ica
l M
an
ife
st
at
io
ns
 a
nd
 A
ge
. 
 
 
 
 
 
 
 
 
 
   
 
   
N
o.
 
A
ge
, y
 
To
ta
l I
gE
, k
U
A
/L
 
Ig
E
 H
Z
N
, k
U
A
/L
 
Ig
E
 C
or
 a
 1
1,
 k
U
A
/L
 
 
 
 
M
ed
ia
n 
R
an
ge
 
P
a 
M
ed
ia
n 
R
an
ge
 
P
a 
M
ed
ia
n 
R
an
ge
 
P
a 
M
ed
ia
n 
R
an
ge
 
P
a  
 
 
 
 
 
 
 
 
 
 
 
 
 
Ab
br
ev
ia
tio
ns
: A
D 
HZ
N
+
, i
nf
an
ts
 u
nd
er
 1
 y
ea
r o
f a
ge
 w
ith
 a
to
pi
c 
de
rm
at
iti
s 
an
d 
po
sit
iv
e 
sIg
E 
to
 h
az
el
nu
t; 
AD
 H
ZN
- , 
in
fa
nt
s 
un
de
r 1
 y
ea
r o
f a
ge
 w
ith
 a
to
pi
c 
de
rm
at
iti
s 
an
d 
ne
ga
tiv
e 
sIg
E 
to
 h
az
el
nu
t; 
HC
, 
he
al
th
y 
co
nt
ro
ls;
 H
ZN
, h
az
el
nu
t; 
HZ
N
-B
P+
, p
at
ie
nt
s 
al
le
rg
ic 
to
 b
irc
h 
po
lle
n 
bu
t t
ol
er
an
t o
f h
az
el
nu
t; 
HZ
N
+
O
AS
+
, h
az
el
nu
t-a
lle
rg
ic 
pa
tie
nt
s 
w
ith
 o
ra
l a
lle
rg
y 
sy
nd
ro
m
e;
 H
ZN
+
SR
+
, h
az
el
nu
t-a
lle
rg
ic 
pa
tie
nt
s 
w
ith
 s
ys
te
m
ic 
re
ac
tio
ns
; s
Ig
E.
 S
pe
cifi
 c
 im
m
un
og
lo
bu
lin
 E
. 
a P
 v
al
ue
s 
de
no
te
 s
ta
tis
tic
al
 s
ig
ni
fi c
an
ce
 b
et
w
ee
n 
pa
tie
nt
s 
an
d 
co
nt
ro
ls 
(M
an
n-
W
hi
tn
ey
 U
 te
st
).
b S
ta
tis
tic
al
ly 
sig
ni
fi c
an
t.
 H
Z
N
+
SR
+
 
Pr
es
ch
oo
l 
22
 
2 
(0
-4
) 
.0
01
b  
34
1 
(1
2-
43
47
) 
.0
2b
 
24
.5
 
(<
0.
10
->
10
0)
 
<
.0
01
b  
<
0.
10
 
(<
0.
10
-0
.6
7)
 
.0
1b
 
 
Sc
ho
ol
 
10
 
10
 
(7
-1
8)
 
– 
55
9 
(8
6-
50
54
) 
.0
09
b  
25
.7
 
(1
.7
2-
>
10
0)
 
<
.0
01
b  
<
0.
10
 
(<
0.
10
-7
.9
8)
 
.0
03
b
 
 
A
du
lts
 
8 
27
.5
 
(2
4-
44
) 
– 
33
9 
(6
4-
17
47
) 
<
.0
01
b  
9.
2 
(<
0.
10
-3
7.
00
) 
<
.0
01
b  
<
0.
10
 
(<
0.
10
-0
.1
5)
 
–
 
 
 
 
To
ta
l 
40
 
 
 
 
 
 
 
 
 
 
 
 
 H
Z
N
+
O
A
S 
Pr
es
ch
oo
l 
6 
4.
5 
(2
-6
) 
– 
41
5 
(2
5-
47
51
) 
.0
3b
 
40
 
(<
0.
10
->
10
0)
 
.0
04
b  
<
0.
10
 
(<
0.
10
-0
.2
2)
 
–
 
 
+
Sc
ho
ol
 
10
 
11
.5
 
(7
-1
6)
 
– 
43
4 
(4
3-
21
68
) 
.0
04
b  
54
.8
 
(1
.4
9-
>
10
0)
 
<
.0
01
b  
<
0.
10
 
(a
ll<
0.
10
) 
–
 
 
A
du
lts
 
24
 
34
 
(1
9-
63
) 
– 
19
7 
(9
-6
79
) 
<
.0
01
b  
11
.7
5 
(<
0.
10
->
10
0)
 
<
.0
01
b  
<
0.
10
 
(a
ll<
0.
10
) 
–
 
 
To
ta
l 
40
 
 
 
 
 
 
 
 
 
 
 
 
 H
C
 
 
Pr
es
ch
oo
l 
5 
5 
(3
-6
) 
 
16
.1
 
(1
6-
27
8)
 
 
<
0.
10
 
(a
ll 
<
0.
10
) 
 
<
0.
10
 
(a
ll<
0.
10
) 
 
 
Sc
ho
ol
 
13
 
10
 
(8
-1
3)
 
 
14
3 
(6
-4
36
) 
 
<
0.
10
 
(a
ll 
<
0.
10
) 
 
<
0.
10
 
(a
ll<
0.
10
) 
 
 
A
du
lts
 
9 
35
 
(2
1-
56
) 
 
32
 
(2
-7
3)
 
 
<
0.
10
 
(a
ll 
<
0.
10
) 
 
<
0.
10
 
(a
ll<
0.
10
)
  
 
To
ta
l 
27
 
 
 
 
 
 
 
 
 
 
 
 
 H
Z
N
- B
P+
 
Pr
es
ch
oo
l 
10
 
4 
(2
-6
) 
– 
19
6 
(1
6-
12
94
) 
– 
12
.2
7 
(0
.3
9-
>
10
0)
 
.0
01
b  
<
0.
10
 
(a
ll<
0.
10
) 
–
 
 
Sc
ho
ol
 
9 
12
 
(7
-1
5)
 
– 
33
3 
(8
8-
17
58
) 
.0
2b
 
8.
9 
(0
.3
4-
86
.7
0)
 
<
.0
01
b  
<
0.
10
 
(a
ll<
0.
10
) 
–
 
 
A
du
lts
 
10
 
33
.5
 
(2
1-
53
) 
– 
19
9 
(5
5-
24
08
) 
<
.0
01
b  
4.
7 
(0
.1
4-
56
.0
0)
 
<
.0
01
b  
<
0.
10
 
(a
ll<
0.
10
) 
–
 
 
To
ta
l 
29
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
ge
, m
o 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A
D
 H
Z
N
+
 
 
24
 
9 
(4
-1
1)
 
– 
22
3 
(7
-2
13
5)
 
<
.0
01
b  
5.
65
 
(0
.4
3-
>
10
0)
 
<
.0
01
b  
<
0.
10
 
(<
0.
10
-0
.4
2)
 
<
.0
01
b
 A
D
 H
Z
N
- 
 
9 
6.
5 
(5
-1
1)
 
– 
25
 
(1
5-
39
6)
 
– 
<
0.
10
 
(<
0.
10
-0
.1
7)
 
– 
<
0.
10
 
(a
ll<
0.
10
) 
–
 H
C
  
  
 
5 
8 
(5
-1
1)
  
  
10
 
(5
-1
7)
 
  
0.
17
 
(0
.1
7-
0.
23
) 
 
<
0.
10
 
(a
ll<
0.
10
) 
–
 
 
To
ta
l 
38
 
 
 
 
 
 
 
 
 
 
 
 
J Investig Allergol Clin Immunol 2012; Vol. 22(4): 245-251 © 2012 Esmon Publicidad
MM Verweij, et al248
50
40
30
20
10
0
%
 P
os
iti
ve
A Bctrls
HZN+SR+
HZN+OAS+
HZN-BP+
<1y
Preschool School Adults ctrls AD HZN+ AD HZN-
Figure 1. A, Sensitization (%) to Cor a 11 in healthy controls (ctrls), patients with a systemic reaction on consumption of hazelnut (HZN+SR+), hazelnut-
allergic patients with OAS only (HZN+OAS+), and patients tolerant of hazelnut but allergic to birch pollen (HZN-BP+). These groups were stratifi ed into 
3 age categories (preschool 0-6 y, 7-18 y, and >18 y). B, Sensitization (%) to Cor a 11 in healthy control infants, infants with atopic dermatitis sensitized 
to hazelnut (AD HZN+), and not sensitized to hazelnut (AD HZN-). All these infants were under 1 year of age. For absolute numbers see Table 1. χ2 
P values <.05 for bars higher than 10% (controls vs patients).
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Figure 2. Percentages of CD63+ basophils after stimulation with 4 
concentrations of Cor a 11 in 8 patients with hazelnut allergy sensitized 
to Cor a 11 (black line) and in 8 control individuals. Five of them were 
allergic to hazelnut but not sensitized to Cor a 11 and the other 3 were 
hazelnut tolerant (dashed line). Results are expressed as the percentage 
of CD63+ basophils (mean [SEM]).
Statistical Analysis
Results were expressed as median values (range). 
Nonparametric tests were used where appropriate and 
frequencies were compared using χ2 analysis. IBM SPSS 17 
(IBM) software was used for data analysis. A P value of less 
than .05 was regarded as statistically signifi cant.
 
Results
 
Age and IgE Levels
Table 1 summarizes the age of the patients, total IgE levels, 
and singleplexed sIgE levels to the Cor a 1.04-spiked hazelnut 
and nCor a 11. 
Sensitization to nCor a 11
Figure 1 displays the percentages of sensitization to 
nCor a 11. The most interesting observations were that 8 (36%) 
of 22 preschool children and 4 (40%) of 10 schoolchildren 
with systemic reactions after consumption of hazelnut were 
sensitized to nCor a 11. By contrast, sensitization to nCor a 11 
was seen only in 1 of the 8 adults with systemic reactions to 
hazelnut and in 2 of the 6 preschool children, but not in the 
school-aged children or adults with OAS. None of the birch-
pollen allergic patients without hazelnut allergy or the healthy 
controls showed IgE reactivity to nCor a 11 (Figure 1A). 
Figure 1B shows that only 2 (8%) of the 24 infants with 
AD with a positive sIgE to hazelnut showed sIgE reactivity to 
nCor a 11. None of the infants with AD without sensitization to 
hazelnut or the healthy control infants displayed sensitization 
to nCor a 11.
Table 2 shows the demographic and clinical data and relevant 
sIgE results for the 17 patients sensitized to nCor a 11. It should 
be noted that 1 of the children with hazelnut allergy in whom 
diagnosis was confi rmed by skin testing showed a negative 
sIgE result to the nCor a 1.04-spiked hazelnut ImmunoCAP. As 
can be seen in Table 2, this child had generalized urticaria and 
angioedema and was monosensitized to nCor a 11. 
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Sensitization to Cross-Reactive 
Carbohydrate Determinants
Seroreactivity to the glycosylated purifi ed 
Cor a 11 could result from sensitization to 
carbohydrate determinants (CCDs), particularly 
grass pollen CCD [20]. Based on the data shown 
in Table 2, 10 (59%) of the 17 patients sensitized 
to Cor a 11 had grass pollen allergy (according 
to clinical history and seroreactivity to the 
recombinant grass pollen specifi c markers Phl p 
(Phleum pratensis) 1, Phl p 2, Phl p 4, Phl p 5, 
Phl p 6 and/or Phl p 11 spotted on the ISAC). 
Only 2 of these 17 patients had evidence of 
sensitization to CCDs [20].
 
BAT With Purifi ed Cor a 11
Figure  2  shows a  dose-dependent 
upregulation of CD63 upon stimulation of 
basophils with purifi ed Cor a 11 in hazelnut-
allergic children sensitized to nCor a 11 (n=8). 
No such upregulation was seen in 5 hazelnut-
allergic patients without sensitization to nCor a 11 
or in 3 healthy, hazelnut-tolerant controls. 
Cor a 11 Compared With Cor a 9
Figure 3 shows the percentages of 
sensitization to nCor a 11 and nCor a 9 in the 
different patient groups. Sensitization to nCor a 11 
and nCor a 9 was mainly seen in children with 
systemic reactions but not in those with OAS. 
Sensitization to nCor a 11, by contrast, was 
hardly present in infants with AD.
 
Discussion
The most interesting and novel observation 
of this study is that sensitization to Cor a 11 in 
our birch-endemic region was seen mainly in 
young children who developed more severe 
clinical symptoms following the consumption 
of hazelnut. Indeed, sensitization to Cor a 11 
was 3 to 4 times more prevalent in preschool 
and schoolchildren than in adults, and was most 
common in patients with systemic reactions. 
Our fi ndings in this respect clearly differ from 
those of Lauer et al [14], who described IgE-
binding to Cor a 11 in almost half of the adult 
population with hazelnut-related OAS tested 
in a birch-endemic region. The exact reason or 
reasons for this discrepancy remain elusive but 
they might be related to the use of different IgE 
assays. By contrast, our data are consistent with 
observations by Hansen et al [6], who, using a 
similar ImmunoCAP technique, were unable to 
confi rm sensitization to Cor a 11 in hazelnut-
allergic adults in a birch-endemic region. 
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Figure 3. Comparison of sensitization (%) to Cor a 11 and Cor a 9 in a birch-endemic region in different groups stratifi ed by age and severity of clinical 
reactions following consumption of hazelnut-containing foods: patients <1 year of age with atopic dermatitis sensitized to hazelnut (AD HZN+) and not 
sensitized to hazelnut (AD HZN-); healthy controls (HC); patients with systemic reactions following consumption of hazelnut-containing foods (HZN+SR+) 
or with mere OAS (HZN+OAS+) divided into 3 groups (preschool, schoolchildren, and adults). For absolute numbers see Table 1. 
It is not clear when or through which route or routes children 
become sensitized to Cor a 11. We therefore extended our study 
by including infants under the age of 1 year with AD, since 
this condition is frequently associated with food sensitization. 
However, there were practically no cases of sensitization to Cor 
a 11 in this population. Therefore, it appears that sensitization 
to vicilins starts at a later age than sensitization to Cor a 9 and 
probably results from 1 or more routes of exposure other than 
in utero sensitization or sensitization through breastfeeding or 
inhalation (eg, oral consumption) [12].
Interestingly, sensitization to Cor a 11 in older patients 
with overt hazelnut allergy, seemed to be generally associated 
with sensitization to Cor a 9, as 13 of the 17 Cor a 11-positive 
patients in our series also had IgE reactivity to Cor a 9. 
A potential criticism of our study, in the absence of double-
blind, placebo-controlled challenges with hazelnut, could be 
that we did not directly assess the clinical relevance of the in 
vitro sIgE observations. However, a positive challenge with 
whole hazelnut does not offer absolute proof that Cor a 11 is 
the offending component. Therefore, in order to further and 
safely investigate the clinical relevance of anti-nCor a 11 sIgE 
antibodies, we performed fl ow-assisted analysis of nCor a 11–
activated basophils. Our fi ndings show that these antibodies, 
even in low titers, can trigger signifi cant activation of basophils 
in an assay that closely resembles the in vivo pathway that 
leads to the symptoms of an allergic reaction. 
Another criticism of our results could be that our 
sensitization data for the purifi ed Cor a 11 are the result 
of sensitization to CCD, as Cor a 11 is glycosylated. This 
would probably indicate clinically irrelevant sensitization. 
However, only 1 out of 10 patients in our series were 
sensitized to CCD.
The present study adds to the observation that hazelnut 
allergy exhibits age-related variations in the severity of 
symptoms according to the sensitization profi le of the patient. 
We have shown that sensitization to Cor a 11 in a birch-endemic 
region predominantly occurs in children with severe hazelnut 
allergy and in preschool children with OAS, but is absent 
in adults with OAS related to their underlying birch pollen 
allergy. Moreover, our fi ndings on sensitization to Cor a 11 
are largely consistent with prior observations of sensitization 
to Cor a 9, another member of the cupin superfamily. In our 
study , however, sensitization to Cor a 9 was absent in patients 
with OAS and onset of sensitization seemed to start earlier in 
life, probably as a result of an alternative route or alternative 
routes of exposure. 
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